Number of pages: 100 | Report Format: PDF | Published date: November 18, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global overactive bladder market was pegged at ~US$ 8.3 billion in 2021 and is expected to witness a CAGR of 4.5% during the forecast period.
The term "overactive bladder" (OAB) refers to a collection of urine symptoms. It's not an illness. Urinary impulses or needs that appear suddenly and without warning are the most typical sign. Treatments for overactive bladder are used to address the abrupt, involuntary contraction of the muscle in the urinary bladder wall that causes nocturia, frequency, urge incontinence, and urine urgency.
An increase in the elderly population and rising public knowledge of the therapies for overactive bladder syndrome are the two main factors driving market expansion for overactive bladder therapy. The overactive bladder treatment market is anticipated to rise as a result of increased investment in the development of novel medications and devices.
The development of unpleasant side effects related to the recommended medication or treatment is the main barrier to the overactive bladder therapies industry. However, market expansion is expected to be constrained by issues like product recalls and societal stigma.
The global overactive bladder market has been analyzed from three perspectives, disease type, type, and region.
Overactive bladder Market by Disease Type
Based on disease type, the global overactive bladder market has been subdivided into, idiopathic overactive bladder and neurogenic overactive bladder. Due to the higher prevalence of idiopathic overactive bladder disorders, the segment for idiopathic overactive bladder syndrome accounted for a larger market share. Additionally, it is anticipated that increased use of SNM therapy for patients with idiopathic overactive bladder will aid in segmental growth.
Overactive Bladder Market by Type
Based on type, the global overactive bladder market has been divided into diagnosis and treatment. The diagnosis segment is further divided into, urine tests, bladder scans, cystoscopy, and others. The treatment segment is further divided into anticholinergics, mirabegron, neurostimulation, intravesical instillation, and others. In the overactive bladder market, anticholinergics enjoy a considerable market share as the first choice of medications for the treatment of overactive bladder syndrome.
Overactive Bladder Market by Region
Based on region, the global overactive bladder market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The prevalence of individuals with overactive bladder in the US and the favorable reimbursement rules for the available treatments are just two of the factors contributing to the North American region's supremacy. Additionally, the desire of market players along with ANDA and FDA approval for various treatments is accelerating the market's expansion in the area.
Some of the prominent players operating in the global overactive bladder market are: -
The global overactive bladder market is expected to grow at a CAGR of % in the forecast period.
Astellas Pharma, Teva Pharmaceuticals, Pfizer Inc., AbbVie Inc. etc. are a few key players in the global overactive bladder market.
The idiopathic overactive bladder segment dominates the global overactive bladder market.
Asia Pacific region is expected to witness the highest global overactive bladder market growth in the forecast period.
*Insights on financial permanence are subject to the availability of information in the public domain